Late filing
elevated
Filing comparison
XTL BIOPHARMACEUTICALS LTD told the SEC it could not file its annual report on time
(the “Company”) is currently facing an unprecedented challenge, rare for public issuers, and therefore unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 (the “Form 20-F”) within the prescribed period due to the liquidation proceedings of the Company’s wholly owned subsidiary, The Social Proxy Ltd. (the “Subsidiary”), and the lack of operational and financial data regarding the Subsidiary required to finalize its audited financial statements and other disclosures in the Form 20-F. The Company expects to file its Annual Report on Form 20-F once the operational and financial information regarding the Subsidiary becomes available or after receiving court…
Evidence
- Days past due date
- 30
- Routine
- No
- Severity
- elevated
- Source
- Form 12b-25 (notification of late filing)
- Stated reason
- (the “Company”) is currently facing an unprecedented challenge, rare for public issuers, and therefore unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 (the “Form 20-F”) within the prescribed period due to the liquidation proceedings of the Company’s wholly owned subsidiary, The Social Proxy Ltd. (the “Subsidiary”), and the lack of operational and financial data regarding the Subsidiary required to finalize its audited financial statements and other disclosures in the Form 20-F. The Company expects to file its Annual Report on Form 20-F once the operational and financial information regarding the Subsidiary becomes available or after receiving court…
- Why
- The company told the SEC it could not file a periodic report on time, using Form 12b-25.